Tous Actualités
Suivre
Abonner AGENNIX AG

AGENNIX AG

EANS-Adhoc: AGENNIX AG
Agennix AG Raises Approximately EUR 76 Million in Net Proceeds in Capital Increase

  ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.
Offering
01.10.2010
Planegg/Munich (Germany), October 1, 2010 - Agennix AG (Frankfurt 
Stock Exchange (Prime Standard): AGX/ISIN DE000A1A6XX4) today 
announced that the Company has raised approximately      EUR 76 
million in net proceeds in its capital increase via participation 
from both new and existing shareholders. The execution of the capital
increase is based on the resolution passed at the Company´s annual 
general meeting on May 25, 2010 to issue 20,588,705 new shares, which
will result in a total of 41,413,846 shares issued and outstanding. 
Subscription rights have been granted to the shareholders. The 
subscription price was EUR 3.81 per share.
In the capital increase, approximately 29% of the 20,588,705 new 
shares were subscribed in the rights offering and approximately 71% 
of the shares were purchased by new institutional investors in a 
private placement or by dievini Hopp BioTech holding GmbH & Co. KG 
under a firm commitment agreement.
Following the completion of this offering, dievini will hold 
approximately 59% of shares outstanding in Agennix.  Dievini has 
informed the Company that it has not yet received a decision from the
German Federal Financial Supervisory Authority (Bundesanstalt fuer 
Finanzdienstleistungsaufsicht) (BaFin) regarding dievini´s 
application for an exemption from the obligation to make a mandatory 
tender offer.  Dievini applied for this exemption in case it acquired
control of the Company in the meaning of Section 29 (2) of the German
Takeover Act through participation in the capital increase.
The entry of the capital increase in the commercial register of the 
local court in Mannheim is expected to occur on or around October 4, 
2010. The new shares will be listed on the Frankfurt Stock Exchange 
and are expected to begin trading on or around October 5, 2010.  The 
Joint Global Coordinators for the transaction were Piper Jaffray Ltd.
and WestLB AG. END OF AD HOC ANNOUNCEMENT About Agennix
Agennix AG is a publicly listed biopharmaceutical company that is 
focused on the development of novel therapies that have the potential
to substantially improve the length and quality of life of critically
ill patients in areas of major unmet medical need. The Company´s most
advanced program is talactoferrin, an oral therapy that has 
demonstrated activity in randomized, double-blind, placebo-controlled
Phase II studies in non-small cell lung cancer, as well as in severe 
sepsis. Talactoferrin is currently in Phase III clinical trials in 
non-small cell lung cancer, and Agennix plans to develop this program
further for the treatment of severe sepsis. Other clinical 
development programs include RGB-286638, a multi-targeted kinase 
inhibitor in Phase I testing; the oral platinum-based compound 
satraplatin; and a topical gel form of talactoferrin for diabetic 
foot ulcers. Agennix´s registered seat is in Heidelberg, Germany. The
Company has three sites of operation: Planegg/Munich, Germany; 
Princeton, New Jersey and Houston, Texas. For additional information,
please visit the Agennix Web site at www.agennix.com.
This ad hoc announcement contains forward-looking statements, which 
express the current beliefs and expectations of the management of 
Agennix AG. Such statements are based on current expectations and are
subject to risks and uncertainties, many of which are beyond our 
control, that could cause future results, performance or achievements
to differ significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Actual 
results could differ materially depending on a number of factors, and
we caution investors not to place undue reliance on the 
forward-looking statements contained in this ad hoc announcement. 
Forward-looking statements speak only as of the date on which they 
are made and Agennix undertakes no obligation to update these 
forward-looking statements, even if new information becomes available
in the future.
This ad hoc announcement is not for distribution, directly or 
indirectly, in or into the United States (including its territories 
and possessions, any State of the United States and the District of 
Columbia). These materials do not constitute or form a part of any 
offer or solicitation to purchase or subscribe for securities in the 
United States of America. The shares in Agennix AG (the "Shares") 
mentioned herein may not be offered or sold in the United States 
absent registration or an exemption from registration under the U.S. 
Securities Act of 1933, as amended (the "Securities Act").
The Shares have not been, and will not be, registered under the 
Securities Act and will not be offered or sold in the United States, 
except on the basis of applicable exemptions from registration. There
will be no public offering of securities in the United States.
end of announcement                               euro adhoc

Further inquiry note:

For further information, please contact:

Agennix AG
Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir@agennix.com

In the U.S.: Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
laurie.doyle@agennix.com

Additional media contact for Europe:
MC Services AG
Raimund Gabriel
Phone: +49 (0) 89 210 228 0
raimund.gabriel@mc-services.eu

Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Vice President
Phone: +44 207 936 9325
lwilliams@troutgroup.com

Branche: Pharmaceuticals
ISIN: DE000A1A6XX4
WKN: A1A6XX
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade

Plus de actualités: AGENNIX AG
Plus de actualités: AGENNIX AG